A compound represented by the following formula (I) or the formula (II) disclosed in the specification is a GPR119 agonist, and is used as an agent for treating diabetes: wherein one of T 1 , T 2 , T 3 , and T 4 is N, and each of the other three independently is CR 4 or, in the alternative, each of the four independently is CR 4 each of R 2 and R 3 is hydrogen or a C 1-8 alkyl group the double line consisting of a solid line and a broken line means a single or double bond A is (CH 2 ) m , a bond, or the like B is (C(R 5 )H) n , a bond, or the like one of U and V is N, and the other is CR 7 W is C or CR 8 each of X and Y is a C 1-3 alkylene group, which optionally has a halogen atom, hydroxyl etc. Z is C(O)OR 9 , C(O)R 10 , or the like.본 발명은 GPR119 작동약인 다음의 일반식 (Ⅰ) 또는 (Ⅱ) 로 나타내는 화합물 또는 그 염, 그리고 이것을 유효 성분으로서 함유하는 당뇨병 치료제에 관한 것이다.T1-4 : 1 개 N, 나머지 CR4 or 모두 CR4, R2-3 : H, C1-8알킬, A : (CH2)1-3, 단결합 등, B : (CR5)1-3, 단결합 등, U, V : 편방 N, 타방 CR7, W-X 간 : 단, 이중 결합, W : C, CR8, X, Y : C1-3알킬렌(Hal, OH 등 치환 가능) 등, Z : COOR9, COR10, 알킬옥사디아졸릴, 알킬피리미딜 등, Q : N, CH, A0 : O, 단결합 등, B0 : (CR25)1-3, 단결합 등, U0, V0 : 편방 N, 타방 CR27, W0-X0 간 : 단, 이중 결합, W0: C, CR28, X0, Y0 : C1-3알킬렌 (Hal, OH 등 치환 가능) 등, Z0: COOR29, COR30, 알킬옥사디아졸릴, 알킬피리미딜 등, R1,7,8,20,27,28 : H, Hal, OH, C1-8알킬 등, R5,25 : H, C1-8알킬, C3-6시클로알킬, R4-5,21-23 : H, C1-8알킬술포닐, 테트라졸릴, 트리아졸릴 등, R9-10,29-30 : C1-8알킬 등
